Hmgb1-IL-23-IL-17-IL-6-Stat3 axis promotes tumor growth in murine models of melanoma

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  Tang, Qiu ^a   Li, Jian ^b   Zhu, Hongfei ^c   Li, Pan ^d   Zou, Zhenwei ^e   Xiao, Yin ^e  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b WUHAN GENERAL HOSPITAL OF GUANGZHOU COMMAND   (China)

^c Wuhan University   (China)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^e UNION HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 6; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 6; STAT3 PROTEIN; ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; HMGB1 PROTEIN, MOUSE; IMMUNOGLOBULIN RECEPTOR; INTERLEUKIN 6, MOUSE; INTERLEUKIN-6, MOUSE; KLRK1 PROTEIN, MOUSE; LYMPHOCYTE ANTIGEN RECEPTOR; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K; STAT3 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; IMMUNOSURVEILLANCE; INOCULATION; MELANOMA; MELANOMA B16; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VOLUME; WILD TYPE; ANIMAL; C57BL MOUSE; EXPERIMENTAL MELANOMA; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CELL PROLIFERATION; HMGB1 PROTEIN; INTERLEUKIN-17; INTERLEUKIN-23; INTERLEUKIN-6; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; RECEPTORS, IMMUNOLOGIC; STAT3 TRANSCRIPTION FACTOR;

EID: 84896353186     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/713859     Document Type: Article

References (44)

1. Wakita D., Sumida K., Iwakura Y., Nishikawa H., Ohkuri T., Chamoto K., Kitamura H., Nishimura T., Tumor-infiltrating IL-17-producing γ δ T cells support the progression of tumor by promoting angiogenesis. European Journal of Immunology 2010 40 7 1927 1937 2-s2.0-77954109936 10.1002/eji.200940157
2. Croci D. O., Zacarías Fluck M. F., Rico M. J., Matar P., Rabinovich G. A., Scharovsky O. G., Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunology, Immunotherapy 2007 56 11 1687 1700 2-s2.0-34548162341 10.1007/s00262-007-0343-y (Pubitemid 47313090)
3. Zou W., Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature Reviews Cancer 2005 5 4 263 274 2-s2.0-16844379997 10.1038/nrc1586 (Pubitemid 40488632)
4. Gaffen S. L., Structure and signalling in the IL-17 receptor family. Nature Reviews Immunology 2009 9 8 556 567 2-s2.0-68849084891 10.1038/nri2586
5. Dong C., Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. Nature Reviews Immunology 2006 6 4 329 333 2-s2.0-33645318217 10.1038/nri1807
6. He D., Wu L., Kim H. K., Li H., Elmets C. A., Xu H., CD8+ IL-17-producing T cells are important in effector functions for the elicitation of contact hypersensitivity responses. Journal of Immunology 2006 177 10 6852 6858 2-s2.0-33750815930 (Pubitemid 44715050)
7. Numasaki M., Watanabe M., Suzuki T., Takahashi H., Nakamura A., McAllister F., Hishinuma T., Goto J., Lotze M. T., Kolls J., Sasaki H., IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. Journal of Immunology 2005 175 9 6177 6189 2-s2.0-27144449330 (Pubitemid 41508106)
8. He D., Wu L., Kim H. K., Li H., Elmets C. A., Xu H., IL-17 and IFN- γ mediate the elicitation of contact hypersensitivity responses by different mechanisms and both are required for optimal responses. Journal of Immunology 2009 183 2 1463 1470 2-s2.0-70249096341 10.4049/jimmunol.0804108
9. Kolls J. K., Lindén A., Interleukin-17 family members and inflammation. Immunity 2004 21 4 467 476 2-s2.0-5644277476 10.1016/j.immuni. 2004.08.018 (Pubitemid 39370503)
10. McGeachy M. J., Cua D. J., Th17 cell differentiation: the long and winding road. Immunity 2008 28 4 445 453 2-s2.0-41549134361 10.1016/j.immuni. 2008.03.001 (Pubitemid 351467042)
11. Kryczek I., Wei S., Szeliga W., Vatan L., Zou W., Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 2009 114 2 357 359 2-s2.0-67651094058 10.1182/blood-2008-09-177360
12. Martin-Orozco N., Muranski P., Chung Y., Yang X. O., Yamazaki T., Lu S., Hwu P., Restifo N. P., Overwijk W. W., Dong C., T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009 31 5 787 798 2-s2.0-70449530422 10.1016/j.immuni.2009.09.014
13. Wang L., Yi T., Kortylewski M., Pardoll D. M., Zeng D., Yu H., IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. Journal of Experimental Medicine 2009 206 7 1457 1464 2-s2.0-67650495415 10.1084/jem.20090207
14. Sims G. P., Rowe D. C., Rietdijk S. T., Herbst R., Coyle A. J., HMGB1 and RAGE in inflammation and cancer. Annual Review of Immunology 2010 28 367 388 2-s2.0-77952298772 10.1146/annurev.immunol.021908.132603
15. Tang D., Kang R., Zeh H. J. III, Lotze M. T., High-mobility group box 1 and cancer. Biochimica et Biophysica Acta 2010 1799 1-2 131 140 2-s2.0-74549175673 10.1016/j.bbagrm.2009.11.014
16. Yan W., Chang Y., Liang X., Cardinal J. S., Huang H., Thorne S. H., Monga S. P., Geller D. A., Lotze M. T., Tsung A., High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology 2012 55 1863 1875
17. Akirav E. M., Preston-Hurlburt P., Garyu J., Henegariu O., Clynes R., Schmidt A. M., Herold K. C., RAGE expression in human T cells: a link between environmental factors and adaptive immune responses. PLoS ONE 2012 7 4 2-s2.0-84859590072 10.1371/journal.pone.0034698 e34698
18. Hee K. K., Zhang H., Li H., Wu T.-T., Swisher S., He D., Wu L., Xu J., Elmets C. A., Athar M., Xu X.-C., Xu H., Slit2 inhibits growth and metastasis of fibrosarcoma and squamous cell carcinoma. Neoplasia 2008 10 12 1411 1420 2-s2.0-57349159203 10.1593/neo.08804
19. He D., Li H., Yusuf N., Elmets C. A., Li J., Mountz J. D., Xu H., IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. Journal of Immunology 2010 184 5 2281 2288 2-s2.0-77951936316 10.4049/jimmunol.0902574
20. Schwarzenberger P., La Russa V., Miller A., Ye P., Huang W., Zieske A., Nelson S., Bagby G. J., Stoltz D., Mynatt R. L., Spriggs M., Kolls J. K., IL-17 stimulates granulopoiesis in mice: use of an alternate, novel gene therapy-derived method for in vivo evaluation of cytokines. Journal of Immunology 1998 161 11 6383 6389 2-s2.0-0032403506 (Pubitemid 28536015)
21. Tang H., Pang S., Wang M., Xiao X., Rong Y., Wang H., Zang Y. Q., TLR4 activation is required for IL-17-induced multiple tissue inflammation and wasting in mice. Journal of Immunology 2010 185 4 2563 2569 2-s2.0-77956928418 10.4049/jimmunol.0903664
22. Kong L. Y., Abou-Ghazal M. K., Wei J., Chakraborty A., Sun W., Qiao W., Fuller G. N., Fokt I., Grimm E. A., Schmittling R. J., Archer G. E. Jr., Sampson J. H., Priebe W., Heimberger A. B., A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clinical Cancer Research 2008 14 18 5759 5768 2-s2.0-53249094201 10.1158/1078-0432.CCR-08-0377
23. Horiguchi A., Asano T., Kuroda K., Sato A., Asakuma J., Ito K., Hayakawa M., Sumitomo M., Asano T., STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma. British Journal of Cancer 2010 102 11 1592 1599 2-s2.0-77952888131 10.1038/sj.bjc.6605691
24. Curtin J. F., Liu N., Candolfi M., Xiong W., Assi H., Yagiz K., Edwards M. R., Michelsen K. S., Kroeger K. M., Liu C., Muhammad A. K., Clark M. C., Arditi M., Comin-Anduix B., Ribas A., Lowenstein P. R., Castro M. G., HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Medicine 2009 6 1 e1000010 10.1371/journal.pmed.1000010
25. Kortylewski M., Kujawski M., Wang T., Wei S., Zhang S., Pilon-Thomas S., Niu G., Kay H., Mulé J., Kerr W. G., Jove R., Pardoll D., Yu H., Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nature Medicine 2005 11 12 1314 1321 2-s2.0-28644445445 10.1038/nm1325 (Pubitemid 41752912)
26. Ostrand-Rosenberg S., Sinha P., Myeloid-derived suppressor cells: linking inflammation and cancer. Journal of Immunology 2009 182 8 4499 4506 2-s2.0-65249138393 10.4049/jimmunol.0802740
27. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pagès C., Tosolini M., Camus M., Berger A., Wind P., Zinzindohoué F., Bruneval P., Cugnenc P.-H., Trajanoski Z., Fridman W.-H., Pagès F., Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006 313 5795 1960 1964 2-s2.0-33749319703 10.1126/science.1129139 (Pubitemid 44498003)
28. Gabrilovich D. I., Nagaraj S., Myeloid-derived suppressor cells as regulators of the immune system. Nature Reviews Immunology 2009 9 3 162 174 2-s2.0-61349100687 10.1038/nri2506
29. Marigo I., Dolcetti L., Serafini P., Zanovello P., Bronte V., Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunological Reviews 2008 222 1 162 179 2-s2.0-41149119143 10.1111/j.1600-065X.2008.00602.x (Pubitemid 351430364)
30. Bronte V., Zanovello P., Regulation of immune responses by L-arginine metabolism. Nature Reviews Immunology 2005 5 8 641 654 2-s2.0-23444456772 10.1038/nri1668 (Pubitemid 41113195)
31. Yu H., Kortylewski M., Pardoll D., Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nature Reviews Immunology 2007 7 1 41 51 2-s2.0-33845865825 10.1038/nri1995 (Pubitemid 46020826)
32. Hirano T., Ishihara K., Hibi M., Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000 19 21 2548 2556 2-s2.0-0034658541 (Pubitemid 30339210)
33. Xiao M., Wang C., Zhang J., Li Z., Zhao X., Qin Z., IFN γ promotes papilloma development by up-regulating th17-associated inflammation. Cancer Research 2009 69 5 2010 2017 2-s2.0-62449162980 10.1158/0008-5472.CAN-08-3479
34. Nam J. S., Terabe M., Kang M. J., Chae H., Voong N., Yang Y. A., Laurence A., Michalowska A., Mamura M., Lonning S., Berzofsky J. A., Wakefield L. M., Transforming growth factor β subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Research 2008 68 10 3915 3923 2-s2.0-45549088943 10.1158/0008-5472.CAN-08-0206
35. Langrish C. L., Chen Y., Blumenschein W. M., Mattson J., Basham B., Sedgwick J. D., McClanahan T., Kastelein R. A., Cua D. J., IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. Journal of Experimental Medicine 2005 201 2 233 240 2-s2.0-13244283212 10.1084/jem.20041257 (Pubitemid 40189432)
36. Langowski J. L., Zhang X., Wu L., Mattson J. D., Chen T., Smith K., Basham B., McClanahan T., Kastelein R. A., Oft M., IL-23 promotes tumour incidence and growth. Nature 2006 442 461 465 2-s2.0-33746534417 10.1038/nature04808 (Pubitemid 44264796)
37. Teng M. W. L., Andrews D. M., McLaughlin N., von Scheidt B., Ngiow S. F., Möller A., Hill G. R., Iwakura Y., Oft M., Smyth M. J., IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis. Proceedings of the National Academy of Sciences of the United States of America 2010 107 18 8328 8333 2-s2.0-77952402724 10.1073/pnas.1003251107
38. Rafa H., Saoula H., Belkhelfa M., Medjeber O., Soufli I., Toumi R., de Launoit Y., Morales O., Nakmouche M., Delhem N., Touil-Boukoffa C., IL-23/IL-17A axis correlates with the nitric oxide Pathway in inflammatory bowel disease: immunomodulatory effect of retinoic acid. Journal of Interferon and Cytokine Research 2013 33 7 355 368
39. Li L., Huang L., Vergis A. L., Ye H., Bajwa A., Narayan V., Strieter R. M., Rosin D. L., Okusa M. D., IL-17 produced by neutrophils regulates IFN- γ -mediated neutrophil migration in mouse kidney ischemia-reperfusion injury. Journal of Clinical Investigation 2010 120 1 331 342 2-s2.0-74949108768 10.1172/JCI38702
40. Chen B., Zeng Z., Xu L., Wu X., Yu J., Xue L., Hao Y., Wang Y., Sung J. J. Y., Chen M., Hu P., IL23R +2199A/C polymorphism is associated with decreased risk of certain subtypes of gastric cancer in Chinese: a case-control study. Cancer Epidemiology 2011 35 2 165 169 2-s2.0-79953103017 10.1016/j.canep.2010. 08.006
41. Ellerman J. E., Brown C. K., de Vera M., Zeh H. J., Billiar T., Rubartelli A., Lotze M. T., Masquerader: high mobility group box-1 and cancer. Clinical Cancer Research 2007 13 10 2836 2848 2-s2.0-34249812086 10.1158/1078-0432.CCR-06-1953 (Pubitemid 46850704)
42. Vernon P. J., Loux T. J., Schapiro N. E., Kang R., Muthuswamy R., Kalinski P., Tang D., Lotze M. T., Zeh H. R., The receptor for advanced glycation end products promotes pancreatic carcinogenesis and accumulation of myeloid-derived suppressor cells. Journal of Immunology 2013 190 1372 1379 10.4049/jimmunol.1201151
43. Kortylewski M., Xin H., Kujawski M., Lee H., Liu Y., Harris T., Drake C., Pardoll D., Yu H., Regulation of the IL-23 and IL-12 balance by stat3 signaling in the tumor microenvironment. Cancer Cell 2009 15 2 114 123 2-s2.0-58649119388 10.1016/j.ccr.2008.12.018
44. Wild C. A., Bergmann C., Fritz G., Schuler P., Hoffmann T. K., Lotfi R., Westendorf A., Brandau S., Lang S., HMGB1 conveys immunosuppressive characteristics on regulatory and conventional T cells. International Immunology 2012 24 485 494